MedTrace Logo

Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS

NCT05653895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-02-23

No results posted yet for this study

Summary

The investigators aim to conduct a double blind randomized clinical trial to study the independent and additive effects of micronutrients (Resveratrol, Acetyl-L Carnitine, L Arginine and COQ10 ) with Metformin in patients with PCOS .Women diagnosed with PCOS according to National Institute of Health( NIH) 2012 extension of European Society of Human Reproduction and Embryology /American Society of Reproductive Medicine ESHRE /ASRM 2003 criteria will be included according to a specific phenotype including Hyperandrogenism, Ovulatory dysfunction and Polycystic Ovarian Morphology. The investigators propose that by using combination therapy with micro supplements like Resveratrol, Acetyl-L Carnitine, L Arginine and COQ10 will produce greater improvement better than or at least comparable to Metformin in metabolic and endocrine profile of patients with PCOS.

Conditions

  • PCOS

Interventions

DIETARY_SUPPLEMENT

Resveratrol

Resveratrol

DRUG

Metformin

Metformin

COMBINATION_PRODUCT

Acetyl-L-Carnitin, L Arginine, Co-Q10

Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10

Sponsors & Collaborators

  • Khyber Medical University Peshawar

    lead OTHER

Principal Investigators

  • Mohsin Shah, PHD · Department of Physiology ,Khyber Medical University ,Peshawar, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-07
Primary Completion
2023-12-30
Completion
2024-02-07

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05653895 on ClinicalTrials.gov